Quarterly ResultMay 13, 2026, 04:37 PM
Lucid Diagnostics Q1 Revenue +51.7% to $1.3M; Net Loss Narrows to $23.6M
AI Summary
Lucid Diagnostics reported a significant increase in revenue and a narrower net loss for the first quarter of 2026. Revenue grew by 51.7% to $1.3 million, and the net loss attributable to common stockholders improved to $23.6 million from $36.0 million in the prior year period. Despite these improvements, the company continues to experience recurring losses and negative cash flows from operations, leading management to raise substantial doubt about its ability to continue as a going concern. Post-quarter, Lucid Diagnostics completed a registered direct offering, securing $16.8 million in net proceeds to support its operations.
Key Highlights
- Revenue increased by 51.7% to $1.3 million for the three months ended March 31, 2026.
- Net loss attributable to common stockholders narrowed to $23.6 million from $36.0 million year-over-year.
- Basic and diluted net loss per share improved to $(0.17) in Q1 2026 from $(0.52) in Q1 2025.
- Cash balance was $27.9 million as of March 31, 2026, down from $34.7 million at December 31, 2025.
- Net cash used in operating activities was $12.1 million for the three months ended March 31, 2026.
- Subsequent to quarter-end, Lucid Diagnostics raised approximately $16.8 million net proceeds from a registered direct offering.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
- The fair value of the 2024 Senior Secured Convertible Notes increased to $25.2 million as of March 31, 2026.